Dr. Simon is a postdoctoral fellow in Stan Riddell’s laboratory at the Fred Hutchinson CRC, Seattle, USA. His studies aim at understanding biological mechanisms associated with anti-tumor efficacy, tumor resistance and therapy-associated toxicities in cancer patients treated with immunotherapy agents. With the support of the LLS CDP special fellow award, he will describe in unprecedented depth the cellular and molecular variations leading to the development of Cytokine Release Syndrome (CRS), the most common and life-threatening toxicity in blood cancer patients receiving CAR-T cell therapies. This program will lead to the description of potential targets for therapeutic intervention to prevent or resolve CRS and therefore preserve anti-tumor efficacy of the CAR-T cell therapy.